This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Jim Cramer's 'Mad Money' Recap: 5 Stocks That Have Buoyed the Dow

But more important, Cramer said history has proven that when other CEOs at public companies have announced similar medical conditions, the dips that followed have always been buying opportunities. That was certainly the case with former Intel CEO Andy Grove and more recently Warren Buffett.

Cramer said Dimon has not been perfect and the company's latest quarter was not spectacular, but overall the company remains a proxy for the growth of the overall U.S. and global economies -- which makes him feel confident enough to keep buying into any weakness.

Cramer Prescribes Drugstores

With the Affordable Care Act giving millions of Americans health care coverage and a slew of drugs going generic, it's a great time to be a drugstore, Cramer told viewers as he re-ranked the three major players Walgreen (WAG), CVS Caremark (CVS - Get Report) and Rite-Aid (RAD - Get Report).

Coming in third is Walgreen, a stock that once topped Cramer's drugstore list. With shares up 27% so far this year, Cramer said the easy money has been made in Walgreen and the stock is priced for perfection, which makes the risk/reward a lot higher and the stock a lot less favorable.

In the number two spot is CVS, a company Cramer admitted he likes a lot. He said CVS is a genius at data mining and giving customers special deals on what they need most. Cramer is also a fan of the company's in-store clinics as well as  national and international growth prospects.

That left Rite-Aid in the pole position. Cramer said this $7 name is still in turnaround mode, with only 30% of its stores updated to its latest format. He said the stock has become a real bargain, down 14% over the past month, on what amounted to a hiccup in the company's latest earnings.

Don't cont Rite-Aid out, Cramer concluded. This stock could easily see double digits in the near future.

Executive Decision: Harold Hamm

For his "Executive Decision" segment, Cramer spoke with Harold Hamm, chairman and CEO of Continental Resources (CLR), one of the leading oil producers in the Bakken shale.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
CVS $103.76 1.20%
JPM $60.65 1.80%
PAYX $49.85 0.61%
RAD $8.80 2.70%
WAG $81.65 2.05%


DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs